Comments can be written based on our submission, or can be as simple as recommending treatments be based on the diagnosis, testing, and treatment guidance found in the ME IC Primer. The ME IC Primer can be seen in multiple languages on our website HIER.

Comments can be submitted either by:

• MAIL to:
     Anindita Issa, MD
     Centers for Disease Control and Prevention
     1600 Clifton Road NE, Mailstop H24-12
     Atlanta, Georgia 30329
  (possibly the easiest option), or
• Through the Federal eRulemaking Portal at http://www.regulations.gov.
  The comment form has two requirements before users can submit a comment: (1) Users must enter content in the comment field, and (2) Users must choose an identity.
  • Users choose an identity from three options:
    1. As an Individual: First and Last Name are required.
    2. On behalf of an Organization: Organization Type and Organization Name are required.
    3. As Anonymous: No additional information is required.

NOTE: The “Submit” button will not activate until the submitter has chosen an identity.

BE SURE to include the Docket No. CDC-2021-0053 when submitting any comments. If you have any questions, or need assistance, please contact Beheerder@ME-International.org.

We hope to expand our comments on the specific clinical information based on the IC Primer as well as information that has come to light since then, like thorough dysautonomia screening, expanded screening for spinal/cranial issues, benefits of ongoing IV fluids, testing for small fiber neuropathy, low dose naltrexone’s benefits to relieve pain, test for NK cell function, etc.